Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis

Jonathan Stine, Nicolas Intagliata, Neeral L. Shah, Curtis K. Argo, Stephen H. Caldwell, James H. Lewis, Patrick G. Northup

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Hyperbilirubinemia is a common side effect of protease inhibitors used to treat chronic hepatitis C (HCV), and most patients do not experience without clinically overt hepatotoxicity. The safety of second-wave protease inhibitors, including simeprevir, has not been well studied in patients with advanced cirrhosis. Materials & Methods: We report two cases of suspected drug-induced liver injury leading to hepatic decompensation in patients with advanced HCV cirrhosis treated with the combination of simeprevir and sofosbuvir on a compassionate basis. Both patients developed marked hyperbilirubinemia out of proportion to their aminotransferases, despite clearance of hepatitis C RNA. RUCAM scoring was probable and possible, respectively. While other factors may have contributed to the liver injury, including infection and concurrent administration of other medications, we believe that the potentially deleterious hepatic effects of simeprevir on transporters or other key functional components were the main reason for their decompensation. Conclusions: Protease inhibitors should be used with caution, if at all, in patients with cirrhosis, especially in those with the most advanced disease. We await newer, safer, direct-acting antiviral therapies for such patients, especially those on our transplant list.

Original languageEnglish (US)
Pages (from-to)1031-1035
Number of pages5
JournalDigestive Diseases and Sciences
Volume60
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Fibrosis
Liver
Protease Inhibitors
Hyperbilirubinemia
Chemical and Drug Induced Liver Injury
Chronic Hepatitis C
Hepatitis C
Transaminases
Antiviral Agents
Simeprevir
RNA
Transplants
Safety
Wounds and Injuries
Infection
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Stine, J., Intagliata, N., Shah, N. L., Argo, C. K., Caldwell, S. H., Lewis, J. H., & Northup, P. G. (2015). Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis. Digestive Diseases and Sciences, 60(4), 1031-1035. https://doi.org/10.1007/s10620-014-3422-x
Stine, Jonathan ; Intagliata, Nicolas ; Shah, Neeral L. ; Argo, Curtis K. ; Caldwell, Stephen H. ; Lewis, James H. ; Northup, Patrick G. / Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis. In: Digestive Diseases and Sciences. 2015 ; Vol. 60, No. 4. pp. 1031-1035.
@article{49ea0e7111b94df391d2bf3fe7093bd9,
title = "Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis",
abstract = "Background: Hyperbilirubinemia is a common side effect of protease inhibitors used to treat chronic hepatitis C (HCV), and most patients do not experience without clinically overt hepatotoxicity. The safety of second-wave protease inhibitors, including simeprevir, has not been well studied in patients with advanced cirrhosis. Materials & Methods: We report two cases of suspected drug-induced liver injury leading to hepatic decompensation in patients with advanced HCV cirrhosis treated with the combination of simeprevir and sofosbuvir on a compassionate basis. Both patients developed marked hyperbilirubinemia out of proportion to their aminotransferases, despite clearance of hepatitis C RNA. RUCAM scoring was probable and possible, respectively. While other factors may have contributed to the liver injury, including infection and concurrent administration of other medications, we believe that the potentially deleterious hepatic effects of simeprevir on transporters or other key functional components were the main reason for their decompensation. Conclusions: Protease inhibitors should be used with caution, if at all, in patients with cirrhosis, especially in those with the most advanced disease. We await newer, safer, direct-acting antiviral therapies for such patients, especially those on our transplant list.",
author = "Jonathan Stine and Nicolas Intagliata and Shah, {Neeral L.} and Argo, {Curtis K.} and Caldwell, {Stephen H.} and Lewis, {James H.} and Northup, {Patrick G.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s10620-014-3422-x",
language = "English (US)",
volume = "60",
pages = "1031--1035",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Kluwer Academic Publishers-Plenum Publishers",
number = "4",

}

Stine, J, Intagliata, N, Shah, NL, Argo, CK, Caldwell, SH, Lewis, JH & Northup, PG 2015, 'Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis', Digestive Diseases and Sciences, vol. 60, no. 4, pp. 1031-1035. https://doi.org/10.1007/s10620-014-3422-x

Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis. / Stine, Jonathan; Intagliata, Nicolas; Shah, Neeral L.; Argo, Curtis K.; Caldwell, Stephen H.; Lewis, James H.; Northup, Patrick G.

In: Digestive Diseases and Sciences, Vol. 60, No. 4, 01.04.2015, p. 1031-1035.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis

AU - Stine, Jonathan

AU - Intagliata, Nicolas

AU - Shah, Neeral L.

AU - Argo, Curtis K.

AU - Caldwell, Stephen H.

AU - Lewis, James H.

AU - Northup, Patrick G.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: Hyperbilirubinemia is a common side effect of protease inhibitors used to treat chronic hepatitis C (HCV), and most patients do not experience without clinically overt hepatotoxicity. The safety of second-wave protease inhibitors, including simeprevir, has not been well studied in patients with advanced cirrhosis. Materials & Methods: We report two cases of suspected drug-induced liver injury leading to hepatic decompensation in patients with advanced HCV cirrhosis treated with the combination of simeprevir and sofosbuvir on a compassionate basis. Both patients developed marked hyperbilirubinemia out of proportion to their aminotransferases, despite clearance of hepatitis C RNA. RUCAM scoring was probable and possible, respectively. While other factors may have contributed to the liver injury, including infection and concurrent administration of other medications, we believe that the potentially deleterious hepatic effects of simeprevir on transporters or other key functional components were the main reason for their decompensation. Conclusions: Protease inhibitors should be used with caution, if at all, in patients with cirrhosis, especially in those with the most advanced disease. We await newer, safer, direct-acting antiviral therapies for such patients, especially those on our transplant list.

AB - Background: Hyperbilirubinemia is a common side effect of protease inhibitors used to treat chronic hepatitis C (HCV), and most patients do not experience without clinically overt hepatotoxicity. The safety of second-wave protease inhibitors, including simeprevir, has not been well studied in patients with advanced cirrhosis. Materials & Methods: We report two cases of suspected drug-induced liver injury leading to hepatic decompensation in patients with advanced HCV cirrhosis treated with the combination of simeprevir and sofosbuvir on a compassionate basis. Both patients developed marked hyperbilirubinemia out of proportion to their aminotransferases, despite clearance of hepatitis C RNA. RUCAM scoring was probable and possible, respectively. While other factors may have contributed to the liver injury, including infection and concurrent administration of other medications, we believe that the potentially deleterious hepatic effects of simeprevir on transporters or other key functional components were the main reason for their decompensation. Conclusions: Protease inhibitors should be used with caution, if at all, in patients with cirrhosis, especially in those with the most advanced disease. We await newer, safer, direct-acting antiviral therapies for such patients, especially those on our transplant list.

UR - http://www.scopus.com/inward/record.url?scp=84934281205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934281205&partnerID=8YFLogxK

U2 - 10.1007/s10620-014-3422-x

DO - 10.1007/s10620-014-3422-x

M3 - Article

C2 - 25373453

AN - SCOPUS:84934281205

VL - 60

SP - 1031

EP - 1035

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -